Venturis Therapeutics   Report issue

For profit Phase 2
Founded: Dallas TX United States (1998)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2005
NCT00425178
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

fgf-1 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arteriosclerosis (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Intermittent Claudication (Phase 1)

Ischemia (Phase 2)

Myocardial Ischemia (Phase 2)

Peripheral Arterial Disease (Phase 1)

Peripheral Vascular Diseases (Phase 1)

Ulcer (Phase 1)

Varicose Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1